The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
α‐Synuclein oligomers and clinical implications for Parkinson disease
Open accessAbstract
Protein aggregation within the central nervous system has been recognized as a defining feature of neurodegenerative diseases since the early 20th century. Since that time, there has been a growing list of neurodegenerative disorders, including Parkinson disease, which are characterized by inclusions of specific pathogenic proteins. This has led to the long‐held dogma that these characteristic protein inclusions, which are composed of large insoluble fibrillar protein aggregates and visible by light microscopy, are responsible for cell death in these diseases. However, the correlation between protein inclusion formation and cytotoxicity is inconsistent, suggesting that another form of the pathogenic proteins may be contributing to neurodegeneration. There is emerging evidence implicating soluble oligomers, smaller protein aggregates not detectable by conventional microscopy, as potential culprits in the pathogenesis of neurodegenerative diseases. The protein α‐synuclein is well recognized to contribute to the pathogenesis of Parkinson disease and is the major component of Lewy bodies and Lewy neurites. However, α‐synuclein also forms oligomeric species, with certain conformations being toxic to cells. The mechanisms by which these α‐synuclein oligomers cause cell death are being actively investigated, as they may provide new strategies for diagnosis and treatment of Parkinson disease and related disorders. Here we review the possible role of α‐synuclein oligomers in cell death in Parkinson disease and discuss the potential clinical implications. ANN NEUROL 2013;73:155–169
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., Rohn, T. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019338 · Cited by 423
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 12×
“Aging is a major risk factor for PD with multiple contributors, including genetic predisposition and environmental insults, altering the normal course of age-related neuronal dysfunction.47,48 The efficacy of the chaperone network, UPS, and ALP are known to decline with age,49 and this may facilitate accumulation of a…”
BackgroundInfluentialSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Signal integration in the endoplasmic reticulum unfolded protein response
Ron, D., & Walter, P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2199 · Cited by 6,296
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454
Molecular chaperones in protein folding and proteostasis
Hartl, F. U., Bracher, A., & Hayer-Hartl, M. (2011) · Nature · doi:10.1038/nature10317 · Cited by 3,381
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Wiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,149
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationα-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,132
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
Self-citationThe toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
Volpicelli-Daley, L. A., Luk, K. C., Patel, T. P., Tanik, S. A., Riddle, D. M., Stieber, A., Meaney, D. F., Trojanowski, J. Q., & Lee, V. M.-Y. (2011) · Neuron · doi:10.1016/j.neuron.2011.08.033 · Cited by 1,569
Hu, C.-D., Chinenov, Y., & Kerppola, T. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00496-3 · Cited by 1,549
Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.
Uéda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., & Saitoh, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11282 · Cited by 1,480
In vivo demonstration that α-synuclein oligomers are toxic
Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100976108 · Cited by 1,463
α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models
Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., Liu, K., Xu, K., Strathearn, K. E., Liu, F., et al. (2006) · Science · doi:10.1126/science.1129462 · Cited by 1,376
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Self-citationSatake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.485 · Cited by 1,324
Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
Bartels, T., Choi, J. G., & Selkoe, D. J. (2011) · Nature · doi:10.1038/nature10324 · Cited by 1,263
Amyloid β-Protein Fibrillogenesis
Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., & Teplow, D. B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22364 · Cited by 1,145
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., Stefanis, L., & Vekrellis, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5699-09.2010 · Cited by 1,115
Identification of two distinct synucleins from human brain
Jakes, R., Spillantini, M. G., & Goedert, M. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00395-5 · Cited by 1,080
α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration
Chandra, S., Gallardo, G., Fernández-Chacón, R., Schlüter, O. M., & Südhof, T. C. (2005) · Cell · doi:10.1016/j.cell.2005.09.028 · Cited by 966
Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein
Cremades, N., Cohen, S. I. A., Deas, E., Abramov, A. Y., Chen, A. Y., Orte, A., Sandal, M., Clarke, R. W., Dunne, P., Aprile, F. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.037 · Cited by 911
The most infectious prion protein particles
Silveira, J. R., Raymond, G. J., Hughson, A. G., Race, R. E., Sim, V. L., Hayes, S. F., & Caughey, B. (2005) · Nature · doi:10.1038/nature03989 · Cited by 899
Cellular strategies for controlling protein aggregation
Tyedmers, J., Mogk, A., & Bukau, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2993 · Cited by 896
Hansen, C., Angot, E., Bergström, A.-L., Steiner, J. A., Pieri, L., Paul, G., Outeiro, T. F., Melki, R., Kallunki, P., Fog, K., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43366 · Cited by 842
In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity
Pike, C. J., Walencewicz, A. J., Glabe, C. G., & Cotman, C. W. (1991) · Brain Research · doi:10.1016/0006-8993(91)91553-d · Cited by 828
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824
Genetic Animal Models of Parkinson's Disease
Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.034 · Cited by 823
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease
Hughes, A. J., Daniel, S. E., & Lees, A. J. (2001) · Neurology · doi:10.1212/wnl.57.8.1497 · Cited by 807
Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., & Lansbury, P. T. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00735-0 · Cited by 805
A common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774
Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding
Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B., & Kostka, M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2617-07.2007 · Cited by 765
El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
Lewandowsky, M. (1912) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-191206000-00015 · Cited by 689
Volles, M. J., Lee, S.-J., Rochet, J.-C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., & Lansbury, P. T. (2001) · Biochemistry · doi:10.1021/bi0102398 · Cited by 682
Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., & Kayed, R. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-39 · Cited by 633
Spira, P. J., Sharpe, D. M., Halliday, G., Cavanagh, J., & Nicholson, G. A. (2001) · Annals of Neurology · doi:10.1002/ana.67 · Cited by 627
Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders
Jucker, M., & Walker, L. C. (2011) · Annals of Neurology · doi:10.1002/ana.22615 · Cited by 622 · cited 1×
“implicated in disease propagation within the nervous system for many neurodegenerative diseases.(110) Support for a-synuclein seeding and a prion-like process in PD”
BackgroundWhat Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP
Dauer, W., Kholodilov, N., Vila, M., Trillat, A.-C., Goodchild, R., Larsen, K. E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172514599 · Cited by 581
Fauvet, B., Mbefo, M. K., Fares, M.-B., Desobry, C., Michael, S., Ardah, M. T., Tsika, E., Coune, P., Prudent, M., Lion, N., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.318949 · Cited by 566
Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., & Selkoe, D. J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00024-2 · Cited by 562
Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains
Alvarez-Erviti, L., Rodriguez-Oroz, M. C., Cooper, J. M., Caballero, C., Ferrer, I., Obeso, J. A., & Schapira, A. H. V. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.198 · Cited by 554
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El-Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 527
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease
Lasagna‐Reeves, C. A., Castillo‐Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., & Kayed, R. (2012) · The FASEB Journal · doi:10.1096/fj.11-199851 · Cited by 527
Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy
Berger, Z., Roder, H., Hanna, A., Carlson, A., Rangachari, V., Yue, M., Wszolek, Z., Ashe, K., Knight, J., Dickson, D., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0587-07.2007 · Cited by 485
Lewy bodies and parkinsonism in families with parkin mutations
Farrer, M., Chan, P., Chen, R., Tan, L., Lincoln, S., Hernandez, D., Forno, L., Gwinn‐Hardy, K., Petrucelli, L., Hussey, J., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1132 · Cited by 485
A soluble α-synuclein construct forms a dynamic tetramer
Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L. T. T., Liao, J., Auclair, J. R., Johnson, D., Landeru, A., Simorellis, A. K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113260108 · Cited by 478
(2002) · doi:10.1016/s0896-6273(02)01125-x · Cited by 473
Assembly-dependent endocytosis and clearance of extracellular a-synuclein
Lee, H.-J., Suk, J.-E., Bae, E.-J., Lee, J.-H., Paik, S. R., & Lee, S.-J. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.01.017 · Cited by 470
AETIOLOGY OF PARKINSON'S DISEASE
Calne, D., & William Langston, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90802-4 · Cited by 469
The propagation of prion-like protein inclusions in neurodegenerative diseases
Goedert, M., Clavaguera, F., & Tolnay, M. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.04.003 · Cited by 454
Harper, J. D., Lieber, C. M., & Lansbury, P. T. (1997) · Chemistry & Biology · doi:10.1016/s1074-5521(97)90303-3 · Cited by 453
Neuropathology provides clues to the pathophysiology of Gaucher disease
Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G. D., Wakefield, L. K., Morrison, A., Lwin, A., Colegial, C., Allman, J. M., et al. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.04.011 · Cited by 452
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3039 · Cited by 449
Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway
Lee, H.-J., Khoshaghideh, F., Patel, S., & Lee, S.-J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3809-03.2004 · Cited by 445
Karpinar, D. P., Balija, M. B. G., Kügler, S., Opazo, F., Rezaei‐Ghaleh, N., Wender, N., Kim, H., Taschenberger, G., Falkenburger, B. H., Heise, H., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.257 · Cited by 432
Cellular Toxicity of Polyglutamine Expansion Proteins
Schaffar, G., Breuer, P., Boteva, R., Behrends, C., Tzvetkov, N., Strippel, N., Sakahira, H., Siegers, K., Hayer-Hartl, M., & Hartl, F. U. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.06.029 · Cited by 425
Glia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 424
Chu, Y., Dodiya, H., Aebischer, P., Olanow, C. W., & Kordower, J. H. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.023 · Cited by 421
Shirendeb, U., Reddy, A. P., Manczak, M., Calkins, M. J., Mao, P., Tagle, D. A., & Hemachandra Reddy, P. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr024 · Cited by 409
Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M., Carvalho, F., Hyman, B. T., & McLean, P. J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001867 · Cited by 401
Self-citationProteasomal Inhibition by α-Synuclein Filaments and Oligomers
Lindersson, E., Beedholm, R., Højrup, P., Moos, T., Gai, W., Hendil, K. B., & Jensen, P. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306390200 · Cited by 397
Endoplasmic Reticulum Stress Is Important for the Manifestations of α-Synucleinopathy In Vivo
Colla, E., Coune, P., Liu, Y., Pletnikova, O., Troncoso, J. C., Iwatsubo, T., Schneider, B. L., & Lee, M. K. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5367-11.2012 · Cited by 389
Matsumine, H., Saito, M., Shimoda‐Matsubayashi, S., Tanaka, H., Ishikawa, A., Nakagawa-Hattori, Y., Yokochi, M., Kobayashi, T., Igarashi, S., Takano, H., et al. (1997) · Europe PMC (PubMed Central) · Cited by 377
Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q
Mori, H., Kondo, T., Yokochi, M., Matsumine, H., Nakagawa-Hattori, Y., Miyake, T., Suda, K., & Mizuno, Y. (1998) · Neurology · doi:10.1212/wnl.51.3.890 · Cited by 370
The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation
Greenbaum, E. A., Graves, C. L., Mishizen-Eberz, A. J., Lupoli, M. A., Lynch, D. R., Englander, S. W., Axelsen, P. H., & Giasson, B. I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411638200 · Cited by 370
Smith, W. W., Jiang, H., Pei, Z., Tanaka, Y., Morita, H., Sawa, A., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi396 · Cited by 365
Preparation and Characterization of Neurotoxic Tau Oligomers
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Jackson, G. R., & Kayed, R. (2010) · Biochemistry · doi:10.1021/bi1016233 · Cited by 359
Neumann, M., Kahle, P. J., Giasson, B. I., Ozmen, L., Borroni, E., Spooren, W., Müller, V., Odoy, S., Fujiwara, H., Hasegawa, M., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15777 · Cited by 355
The role of α-synuclein in Parkinson's disease: insights from animal models
Maries, E., Dass, B., Collier, T. J., Kordower, J. H., & Steece-Collier, K. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1199 · Cited by 344
Tayebi, N. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00071-4 · Cited by 327
Colla, E., Jensen, P. H., Pletnikova, O., Troncoso, J. C., Glabe, C., & Lee, M. K. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5368-11.2012 · Cited by 323
THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE
GIBB, W. R. G., & LEES, A. J. (1989) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1989.tb01147.x · Cited by 319
Khan, N. L., Jain, S., Lynch, J. M., Pavese, N., Abou-Sleiman, P., Holton, J. L., Healy, D. G., Gilks, W. P., Sweeney, M. G., Ganguly, M., et al. (2005) · Brain · doi:10.1093/brain/awh667 · Cited by 317
Danzer, K. M., Ruf, W. P., Putcha, P., Joyner, D., Hashimoto, T., Glabe, C., Hyman, B. T., & McLean, P. J. (2011) · The FASEB Journal · doi:10.1096/fj.10-164624 · Cited by 312
Self-citationGranular Tau Oligomers as Intermediates of Tau Filaments
Maeda, S., Sahara, N., Saito, Y., Murayama, M., Yoshiike, Y., Kim, H., Miyasaka, T., Murayama, S., Ikai, A., & Takashima, A. (2007) · Biochemistry · doi:10.1021/bi061359o · Cited by 308
Cellular stress response pathways and ageing: intricate molecular relationships
Kourtis, N., & Tavernarakis, N. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.162 · Cited by 302
Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease
Maeda, S., Sahara, N., Saito, Y., Murayama, S., Ikai, A., & Takashima, A. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.11.009 · Cited by 301
A Diversity of Assembly Mechanisms of a Generic Amyloid Fold
Eichner, T., & Radford, S. E. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.05.012 · Cited by 292
Minton, A. P. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20417 · Cited by 288
Wacker, J. L., Zareie, M. H., Fong, H., Sarikaya, M., & Muchowski, P. J. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb860 · Cited by 283
Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds
Caruana, M., Högen, T., Levin, J., Hillmer, A., Giese, A., & Vassallo, N. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.046 · Cited by 273
Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?
Cohen, P., & Tcherpakov, M. (2010) · Cell · doi:10.1016/j.cell.2010.11.016 · Cited by 271
Ross, O. A., Toft, M., Whittle, A. J., Johnson, J. L., Papapetropoulos, S., Mash, D. C., Litvan, I., Gordon, M. F., Wszolek, Z. K., Farrer, M. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20731 · Cited by 268
Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic
Takahashi, T., Kikuchi, S., Katada, S., Nagai, Y., Nishizawa, M., & Onodera, O. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm311 · Cited by 258
Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations
van de Warrenburg, B. P. C., Lammens, M., Lücking, C. B., Denèfle, P., Wesseling, P., Booij, J., Praamstra, P., Quinn, N., Brice, A., & Horstink, M. W. I. M. (2001) · Neurology · doi:10.1212/wnl.56.4.555 · Cited by 255
Are synucleinopathies prion-like disorders?
Angot, E., Steiner, J. A., Hansen, C., Li, J.-Y., & Brundin, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70213-1 · Cited by 251
Lewy body Parkinson's disease in a large pedigree with 77Parkin mutation carriers
Pramstaller, P. P., Schlossmacher, M. G., Jacques, T. S., Scaravilli, F., Eskelson, C., Pepivani, I., Hedrich, K., Adel, S., Gonzales-McNeal, M., Hilker, R., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20587 · Cited by 247
Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain
Fuchs, J., Tichopad, A., Golub, Y., Munz, M., Schweitzer, K. J., Wolf, B., Berg, D., Mueller, J. C., & Gasser, T. (2008) · The FASEB Journal · doi:10.1096/fj.07-9348com · Cited by 247
In Vitro and In Vivo Neurotoxicity of Prion Protein Oligomers
Simoneau, S., Rezaei, H., Salès, N., Kaiser-Schulz, G., Lefebvre-Roque, M., Vidal, C., Fournier, J.-G., Comte, J., Wopfner, F., Grosclaude, J., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030125 · Cited by 240
Biochemical and pathological characterization of Lrrk2
Giasson, B. I., Covy, J. P., Bonini, N. M., Hurtig, H. I., Farrer, M. J., Trojanowski, J. Q., & Van Deerlin, V. M. (2006) · Annals of Neurology · doi:10.1002/ana.20791 · Cited by 238
Legleiter, J., Mitchell, E., Lotz, G. P., Sapp, E., Ng, C., DiFiglia, M., Thompson, L. M., & Muchowski, P. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.093708 · Cited by 235
Paleologou, K. E., Kragh, C. L., Mann, D. M. A., Salem, S. A., Al-Shami, R., Allsop, D., Hassan, A. H., Jensen, P. H., & El-Agnaf, O. M. A. (2008) · Brain · doi:10.1093/brain/awn349 · Cited by 228
Forno, L. S. (1969) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1969.tb01316.x · Cited by 215
Hayashi, S., Wakabayashi, K., Ishikawa, A., Nagai, H., Saito, M., Maruyama, M., Takahashi, T., Ozawa, T., Tsuji, S., & Takahashi, H. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5<884::aid-mds1019>3.0.co;2-8 · Cited by 212
Ubiquitin–proteasome system and Parkinson's disease
Olanow, C. W., & McNaught, K. S. P. (2006) · Movement Disorders · doi:10.1002/mds.21013 · Cited by 212
Parkinsonism, Lrrk2 G2019S, and tau neuropathology
Rajput, A., Dickson, D. W., Robinson, C. A., Ross, O. A., Dächsel, J. C., Lincoln, S. J., Cobb, S. A., Rajput, M. L., & Farrer, M. J. (2006) · Neurology · doi:10.1212/01.wnl.0000240220.33950.0c · Cited by 211
Overview of the Extranigral Aspects of Parkinson Disease
Lim, S.-Y., Fox, S. H., & Lang, A. E. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.561 · Cited by 207
Self-citationBAG5 Inhibits Parkin and Enhances Dopaminergic Neuron Degeneration
Kalia, S. K., Lee, S., Smith, P. D., Liu, L., Crocker, S. J., Thorarinsdottir, T. E., Glover, J. R., Fon, E. A., Park, D. S., & Lozano, A. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.026 · Cited by 202
Self-citationLewy Body-Related α-Synucleinopathy in Aging
Saito, Y., Ruberu, N. N., Sawabe, M., Arai, T., Kazama, H., Hosoi, T., Yamanouchi, H., & Murayama, S. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.7.742 · Cited by 200
El-Agnaf, O. M. A., Paleologou, K. E., Greer, B., Abogrein, A. M., King, J. E., Salem, S. A., Fullwood, N. J., Benson, F. E., Hewitt, R., Ford, K. J., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-1346fje · Cited by 187
Lu, J.-H., Tan, J.-Q., Durairajan, S. S. K., Liu, L.-F., Zhang, Z.-H., Ma, L., Shen, H.-M., Chan, H. Y. E., & Li, M. (2012) · Autophagy · doi:10.4161/auto.8.1.18313 · Cited by 184
Curcumin Prevents Aggregation in α-Synuclein by Increasing Reconfiguration Rate
Ahmad, B., & Lapidus, L. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.325548 · Cited by 184
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders
Goker-Alpan, O., Stubblefield, B. K., Giasson, B. I., & Sidransky, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0741-7 · Cited by 181
Putcha, P., Danzer, K. M., Kranich, L. R., Scott, A., Silinski, M., Mabbett, S., Hicks, C. D., Veal, J. M., Steed, P. M., Hyman, B. T., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158436 · Cited by 179
Self-citationSNCA Variant Associated With Parkinson Disease and Plasma α-Synuclein Level
Mata, I. F., Shi, M., Agarwal, P., Chung, K. A., Edwards, K. L., Factor, S. A., Galasko, D. R., Ginghina, C., Griffith, A., Higgins, D. S., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.279 · Cited by 177
CHIP Targets Toxic α-Synuclein Oligomers for Degradation
Tetzlaff, J. E., Putcha, P., Outeiro, T. F., Ivanov, A., Berezovska, O., Hyman, B. T., & McLean, P. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802283200 · Cited by 175
Self-citationPrion protein at the crossroads of physiology and disease
Biasini, E., Turnbaugh, J. A., Unterberger, U., & Harris, D. A. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.10.002 · Cited by 169
Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat
Kordower, J. H., Dodiya, H. B., Kordower, A. M., Terpstra, B., Paumier, K., Madhavan, L., Sortwell, C., Steece-Collier, K., & Collier, T. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.001 · Cited by 169
Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers
Yamin, G., Uversky, V. N., & Fink, A. L. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00367-3 · Cited by 167
Sathasivam, K., Lane, A., Legleiter, J., Warley, A., Woodman, B., Finkbeiner, S., Paganetti, P., Muchowski, P. J., Wilson, S., & Bates, G. P. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp467 · Cited by 167
CLINICAL RELEVANCE OF SPECIFIC IgG ANTIBODIES TO CARDIOLIPIN
Faux, J. A., Byron, M. A., & Chapel, H. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92069-2 · Cited by 165
Emadi, S., Barkhordarian, H., Wang, M. S., Schulz, P., & Sierks, M. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.089 · Cited by 163
Brain stem pathology in Parkinson's disease: An evaluation of the Braak staging model
Kingsbury, A. E., Bandopadhyay, R., Silveira‐Moriyama, L., Ayling, H., Kallis, C., Sterlacci, W., Maeir, H., Poewe, W. H., & Lees, A. J. (2010) · Movement Disorders · doi:10.1002/mds.23305 · Cited by 161
A tale on animal models of Parkinson's disease
Bezard, E., & Przedborski, S. (2011) · Movement Disorders · doi:10.1002/mds.23696 · Cited by 159
Amyloid-β immunisation for Alzheimer's disease
Wisniewski, T., & Konietzko, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70170-4 · Cited by 155
Kalia, L. V., Kalia, S. K., Chau, H., Lozano, A. M., Hyman, B. T., & McLean, P. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014695 · Cited by 149
Self-citationSato, H., Arawaka, S., Hara, S., Fukushima, S., Koga, K., Koyama, S., & Kato, T. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3967-11.2011 · Cited by 142
Formation and Toxicity of Soluble Polyglutamine Oligomers in Living Cells
Lajoie, P., & Snapp, E. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015245 · Cited by 142
Rab11a and HSP90 Regulate Recycling of Extracellular α-Synuclein
Liu, J., Zhang, J., Shi, M. Y., Quinn, T. J., Bradner, J. M., Beyer, R., Chen, S., & Zhang, J. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.6202-08.2009 · Cited by 137
A critical evaluation of the ubiquitin–proteasome system in Parkinson's disease
Cook, C. N., & Petrucelli, L. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.01.012 · Cited by 129
Kikuchi, A., Takeda, A., Okamura, N., Tashiro, M., Hasegawa, T., Furumoto, S., Kobayashi, M., Sugeno, N., Baba, T., Miki, Y., et al. (2010) · Brain · doi:10.1093/brain/awq091 · Cited by 118
Hasegawa, K., Stoessl, A. J., Yokoyama, T., Kowa, H., Wszołek, Z. K., & Yagishita, S. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.07.010 · Cited by 118
Martin, Z. S., Neugebauer, V., Dineley, K. T., Kayed, R., Zhang, W., Reese, L. C., & Taglialatela, G. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07576.x · Cited by 117
Parkin-positive autosomal recessive juvenile parkinsonism with α-synuclein-positive inclusions
Sasaki, S., Shirata, A., Yamane, K., & Iwata, M. (2004) · Neurology · doi:10.1212/01.wnl.0000134657.25904.0b · Cited by 114
G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies
Gaig, C., Martı́, M. J., Ezquerra, M., Rey, M. J., Cardozo, A., & TOLOSA, E. S. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.107904 · Cited by 112
Tsika, E., Moysidou, M., Guo, J., Cushman-Nick, M., Gannon, P. J., Sandaltzopoulos, R., Giasson, B. I., Krainc, D., Ischiropoulos, H., & Mazzulli, J. R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4977-09.2010 · Cited by 110
Genetic neuropathology of Parkinson's disease.
Cookson, M., Hardy, J., & Lewis, P. A. (2008) · PubMed Central · Cited by 108
Molecular Chaperones as Rational Drug Targets for Parkinsons Disease Therapeutics
Kalia, S. K., Kalia, L. V., & McLean, P. J. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710793237386 · Cited by 103
Self-citationLi, M., Chevalier-Larsen, E. S., Merry, D. E., & Diamond, M. I. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609972200 · Cited by 100
Detecting Morphologically Distinct Oligomeric Forms of α-Synuclein
Emadi, S., Kasturirangan, S., Wang, M. S., Schulz, P., & Sierks, M. R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806559200 · Cited by 100
CD45 Deficiency Drives Amyloid-β Peptide Oligomers and Neuronal Loss in Alzheimer's Disease Mice
Zhu, Y., Hou, H., Rezai-Zadeh, K. P., Giunta, B. N., Ruscin, A., Gemma, C., Jin, J., Dragicevic, N., Bradshaw, P. C., Rasool, S., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3268-10.2011 · Cited by 99
Hinault, M., Cuendet, A. F. H., Mattoo, R. U. H., Mensi, M., Dietler, G., Lashuel, H. A., & Goloubinoff, P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127753 · Cited by 84
Hüls, S., Högen, T., Vassallo, N., Danzer, K. M., Hengerer, B., Giese, A., & Herms, J. W. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07254.x · Cited by 81
Vitte, J., Traver, S., de Paula, A. M., Lesage, S., Rovelli, G., Corti, O., Duyckaerts, C. J., & Brice, A. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181efc01c · Cited by 81
Jelliffe (1911) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-191105000-00015 · Cited by 80
Yamamura, Y., Hattori, N., Matsumine, H., Kuzuhara, S., & Mizuno, Y. (2000) · Brain and Development · doi:10.1016/s0387-7604(00)00130-3 · Cited by 76
Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2
Martí-Massó, J. F., Ruiz‐Martínez, J., Bolaño, M. J., Ruiz, I., Gorostidi, A., Moreno, F., Ferrer, I., & de Munaín, A. L. (2009) · Movement Disorders · doi:10.1002/mds.22677 · Cited by 72
Antibodies against Alpha-Synuclein Reduce Oligomerization in Living Cells
Näsström, T., Gonçalves, S. A., Sahlin, C., Nordström, E. K. L., Sundquist, V. S., Lannfelt, L., Bergström, J. J. E., Outeiro, T. F., & Ingelsson, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027230 · Cited by 70
Correction: Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M., Carvalho, F., Hyman, B. T., & McLean, P. J. (2008) · PLoS ONE · doi:10.1371/annotation/9282f173-df82-4b70-9120-b4e62b3dacb1 · Cited by 56
Self-citationClinical and pathological characteristics of patients with Leucine‐rich repeat kinase‐2 mutations
Covy, J. P., Yuan, W., Waxman, E. A., Hurtig, H. I., Deerlin, V. M. V., & Giasson, B. I. (2008) · Movement Disorders · doi:10.1002/mds.22096 · Cited by 55
Glucocerebrosidase mutations in diffuse Lewy body disease
Nishioka, K., Ross, O. A., Vilariño‐Güell, C., Cobb, S. A., Kachergus, J. M., Mann, D. M. A., Snowden, J. S., Richardson, A. M. T., Neary, D., Robinson, C. A., et al. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.09.009 · Cited by 55
Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation
Giordana, M. T., D’Agostino, C., Albani, G., Mauro, A., Fonzo, A. D., Antonini, A., & Bonifati, V. (2006) · Movement Disorders · doi:10.1002/mds.21281 · Cited by 48
Jochum, T., Ritz, M. E., Schuster, C., Funderburk, S. F., Jehle, K., Schmitz, K., Brinkmann, F., Hirtz, M., Moss, D., & Cato, A. C. B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.006 · Cited by 42
Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD
Poulopoulos, M., Cortes, E. P., Vonsattel, J., Fahn, S., Waters, C., COTE, L. J., Moskowitz, C. B., Honig, L. S., Clark, L. N., Marder, K. S., et al. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9696-y · Cited by 42
Gaig, C., Ezquerra, M., Martı́, M. J., Valldeoriola, F., Muñoz, E., Lladó, A., Rey, M. J., Cardozo, A., Molinuevo, J. L., & TOLOSA, E. S. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.02.010 · Cited by 38
Gomez, A., & Ferrer, I. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0669-y · Cited by 34
Split GFP Complementation Assay for Quantitative Measurement of Tau Aggregation In Situ
Chun, W., Waldo, G. S., & Johnson, G. V. W. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-744-0_9 · Cited by 23
Prion protein oligomers in Creutzfeldt‐Jakob disease detected by gel‐filtration centrifuge columns
Minaki, H., Sasaki, K., Honda, H., & Iwaki, T. (2009) · Neuropathology · doi:10.1111/j.1440-1789.2009.01007.x · Cited by 20
G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies
Gaig, C., Martı́, M. J., Ezquerra, M., Cardozo, A., Rey, M. J., & TOLOSA, E. S. (2009) · BMJ Case Reports · doi:10.1136/bcr.08.2008.0632 · Cited by 20
WITHDRAWN: Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice
Liu, K., Liu, C., Shen, L., Shi, J., Zhang, T., Zhou, Y., Zhou, L., & Sun, X. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.011 · Cited by 7
(1999) · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Self-citationAgeing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A., Simcox, E., & Turnbull, D. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 947
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Protective and toxic roles of dopamine in Parkinson's disease
Segura‐Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12686 · Cited by 498
Metadata
- Authors
- Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., & Lang, A. E.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-12-07
- Volume
- 73
- Issue
- 2
- Pages
- 155-169
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1588992473
- Cited by
- 292
- References
- 173
- FWCI
- 17.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.